Hyperfine
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | <1m | 1.5m | 6.8m | 11.0m | 14.2m | 19.1m | 23.8m |
% growth | - | 409 % | 355 % | 62 % | 29 % | 34 % | 25 % |
EBITDA | (23.2m) | (64.1m) | (72.9m) | (47.1m) | (40.7m) | (39.4m) | (38.4m) |
% EBITDA margin | (7892 %) | (4288 %) | (1069 %) | (427 %) | (286 %) | (207 %) | (161 %) |
Profit | (23.4m) | (64.9m) | (73.2m) | (44.2m) | (40.9m) | (39.7m) | (37.9m) |
% profit margin | (7968 %) | (4335 %) | (1074 %) | (401 %) | (287 %) | (208 %) | (159 %) |
EV / revenue | - | 339.4x | 8.7x | 7.3x | 5.2x | 3.8x | 3.1x |
EV / EBITDA | - | -7.9x | -0.8x | -1.7x | -1.8x | -1.9x | -1.9x |
R&D budget | 14.6m | 25.8m | 28.2m | 22.5m | - | - | - |
R&D % of revenue | 4964 % | 1727 % | 413 % | 204 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Seed | |
N/A | N/A | Series C | |
$1.6m | Grant | ||
$90.0m | Series D | ||
$207m Valuation: $580m 1972.8x EV/LTM Revenues -25.0x EV/LTM EBITDA | SPAC IPO | ||
$126m Valuation: $580m 1972.8x EV/LTM Revenues -25.0x EV/LTM EBITDA | SPAC Private Placement | ||
* | $3.0m | Grant | |
Total Funding | $221m |
Related Content
Recent News about Hyperfine
EditHyperfine, Inc. is a pioneering health technology company that has developed the Swoop system, the first FDA-cleared, portable, ultra-low field magnetic resonance imaging (MRI) system. The Swoop system is designed to bring MR brain imaging directly to the patient's bedside, particularly in intensive care units, thereby eliminating the need to transport critically ill patients to radiology departments. This innovation allows for timelier treatment decisions, quicker patient discharges, and more efficient use of hospital staff and resources. The system's open and safe design also enables family members to stay close and provide comfort during imaging procedures. Hyperfine's primary clients include hospitals, clinics, and other healthcare facilities that require accessible and efficient diagnostic imaging solutions. The company operates in the global healthcare market, focusing on improving patient care through advanced imaging technology. Hyperfine generates revenue by selling its Swoop system and related services to healthcare providers. The business model is centered around providing a cost-effective, portable MRI solution that enhances clinical decision-making and patient outcomes.
Keywords: portable MRI, ultra-low field, brain imaging, point-of-care, FDA-cleared, healthcare technology, patient care, diagnostic imaging, intensive care, clinical efficiency.